Lichen planus: altered AIM2 and NLRP1 expression in skin lesions and defective activation in peripheral blood mononuclear cells

Imagem de Miniatura
Arquivos
art_DOMINGUES_Lichen_planus_altered_AIM2_and_NLRP1_expression_in_2019.PDF (2.78 MB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
DOMINGUES, R.
Citação
CLINICAL AND EXPERIMENTAL DERMATOLOGY, v.44, n.4, p.E89-E95, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Lichen planus (LP) is an inflammatory skin disease with unknown aetiology. Activation by pathogen-associated molecular patterns or environmental stimuli may activate some components of inflammasomes that contribute to the inflammatory process in LP lesions. Aim To characterize the inflammasomes in skin lesions and peripheral blood mononuclear cells (PBMCs) of patients with LP under Toll-like receptor (TLR) activation. Methods In total, 15 patients with LP and 14 healthy controls (HCs) were enrolled in the study. Inflammasome expression in skin was evaluated by real-time PCR and immunohistochemistry, while ELISA was used to assess the production of interleukin (IL)-1 beta by PBMCs under stimulation with TLR4 and TLR7/TLR8 agonists and adenosine triphosphate (ATP). Results Compared with the levels in HC samples, increased expression of the inflammasome AIM2 was verified in both epidermal and dermal sections of LP skin lesions, whereas NLRP1 and IL-beta expression levels were enhanced in the dermis. LP skin lesion samples exhibited higher AIM2 transcript levels, similar NLRP1 levels and lower pro-IL-1 beta mRNA levels compared with HC samples. We verified that, compared with PBMCs from HC subjects, PBMCs from patients with LP produced similar amounts of IL-1 beta after induction by TLR4 agonists but lower IL-1 beta levels after induction by TLR7/TLR8 agonists, regardless of the addition of ATP. Conclusion Alterations in innate immunity, such as inflammasome component expression in skin lesions and PBMCs, were observed in patients with LP. Further investigations of dysfunctional inflammasome activation and the chronic inflammatory status of LP are required.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/32532
Referências
  1. BOYD AS, 1991, J AM ACAD DERMATOL, V25, P593, DOI 10.1016/0190-9622(91)70241-S
  2. Cardoso EC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067036
  3. Dai X, 2017, EXP DERMATOL, V26, P1
  4. de Carvalho GC, 2018, ARCH DERMATOL RES, V310, P523, DOI 10.1007/s00403-018-1837-5
  5. de Koning HD, 2012, EXP DERMATOL, V21, P961, DOI 10.1111/exd.12037
  6. de Lollo C, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0900-2
  7. Nogueira MAD, 2015, ARCH DERMATOL RES, V307, P259, DOI 10.1007/s00403-014-1524-0
  8. Domingues R, 2015, BRIT J DERMATOL, V172, P48, DOI 10.1111/bjd.13214
  9. Franchi L, 2007, EUR J IMMUNOL, V37, P3030, DOI 10.1002/eji.200737532
  10. Gorouhi F, 2014, SCI WORLD J, DOI 10.1155/2014/742826
  11. Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006
  12. Gurung P, 2015, J CLIN INVEST, V125, P1329, DOI 10.1172/JCI79526
  13. Janardhanam SB, 2012, ARCH ORAL BIOL, V57, P495, DOI 10.1016/j.archoralbio.2011.10.013
  14. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  15. Pereira NZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084917
  16. Salem A, 2018, EUR J ORAL SCI, V126, P244, DOI 10.1111/eos.12416
  17. Thwaites R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00001
  18. Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/53
Artigos e Materiais de Revistas Científicas - LIM/56
Artigos e Materiais de Revistas Científicas - ODS/03